(NASDAQ: CNTA) Centessa Pharmaceuticals's forecast annual revenue growth rate of -61.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.12%.
Centessa Pharmaceuticals's revenue in 2025 is $15,000,000.On average, 17 Wall Street analysts forecast CNTA's revenue for 2025 to be $2,265,042,693, with the lowest CNTA revenue forecast at $1,976,383,189, and the highest CNTA revenue forecast at $4,687,389,354. On average, 15 Wall Street analysts forecast CNTA's revenue for 2026 to be $422,166,205, with the lowest CNTA revenue forecast at $0, and the highest CNTA revenue forecast at $4,781,099,496.
In 2027, CNTA is forecast to generate $430,636,419 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $4,876,691,907.